- -- Quick Links --
-
- Home
- The focus
- Organizers
- FABA
- Pharmexcil
- Industry Speak
- BioAsia 2012
- BioAsia 2011
- BioAsia 2010
- BioAsia 2009
- Proceedings 2012
- Proceedings 2011
- Proceedings 2010
- Proceedings 2009
- Awards-2012
- Awards-2011
- Awards-2010
- Awards-2009
- Photo Gallery 2012
- Photo Gallery 2011
- Photo Gallery 2010
- Photo Gallery 2009
- Video Gallery 2012
- Video Gallery 2011
- Presentation
- Publications
- Contact Us
Archives
Archives
Agri
Dr. Arvind Kapur
Dr. Arvind Kapur is CEO of vegetable division of Rasi Seeds (P)Ltd., the former M.D. & Head R & D –Asia Pacific of the Nunhems India Pvt Ltd. with rich experience in the Indian seed industry. He was awarded a Doctorate in Plant Biochemistry from Punjab Agricultural University, Ludhiana in 1980.
Dr. William D. Provine
Dr. William D. Provine is currently the Science Director of the Biochemical Science and Engineering – BioFuels division of Central Research and Development at DuPont. In his current role,
Dr. Paresh Varma
Dr. Verma holds a Ph. D. in Agronomy with specialization in Breeding from University of Nebraska and M.Sc.Ag Plant Breeding from GB Pant University of Agriculture and Technology, PantNagar
Dr. Vijay Raghavan
Chairman and President of Sathguru Management Consultants, Hyderabad
Vijayaraghavan (Vijay) is the Chairman and President of Sathguru Management Consultants, India based technology management advisory and strategic consultancy body that is engaged in technology management services over 25 countries in the world.
Dr.Pratibha Singh
Pratibha has completed her Ph. D from Tottori University, Japan with major in Plant Pathology in 2000. She has more than ten years of research experience in molecular plant pathology on various fungal diseases of cereal crops
Dr. Jun Yu
Dr. Jun Yu is currently a professor and Associate Director of Beijing Genomics Institute, Chinese Academy of Sciences (CAS). He has joint appointments and supervises graduate students at the Institute of Computer Sciences (CAS), Zhejiang University, and Chinese Agricultural University
Mr. Ranjeesh Kumar
With a career spanning over 15 years, Rajneesh has held various leadership positions across several Industries and in the Senior Management Cadre of Indian Civil Services. In his role with Monsanto, which he joined in 2010, as the Director – Corporate Affairs, his key responsibility will be developing and leading strategy as part of Corporate Affairs team to achieve business goals, by working closely with diverse set of stakeholders.
Ms. Nora Alonso
Nora Alonso Casajús, biology PhD, is coauthor of 11 publications in international journals and 2 international patents. She has take part in 38 scientific meetings
She is entrepreneur and founder of the biotechnological company Iden Biotechnology (www.idenbiotechnology.com). From June 2005 is the Managing Director and President of the company.
Ms. Xana Melissa Belastegvi
Mrs. Xana Belastegui graduated from the University of the Basque Country (Spain) in 2000 with a degree in Biological Sciences and holds a Ph.D. in Biological Sciences since 2004. Since she graduated, Mrs. Belastegui has been developing her scientific career in public institutions both in Spain and abroad
Pogaku Ravindra
Prof.Dr.Pogaku Ravindra is an internationally renowned expert in bio energy and Biofuels field. He is a distinguished Professor of Chemical and Bioprocess Engineering, and the Postgraduate coordinator of School of Engineering and Information Technology at University Malaysia Sabah (UMS), Kota kinabalu, Sabah, Malaysia.
Prof. Ruplal
Prof.Dr.Pogaku Ravindra is an internationally renowned expert in bio energy and Biofuels field. He is a distinguished Professor of Chemical and Bioprocess Engineering, and the Postgraduate coordinator of School of Engineering and Information Technology at University Malaysia Sabah (UMS), Kota kinabalu, Sabah, Malaysia.
Company Presentations
Bhaskar Venepalli
Bhaskar Venepalli, Ph.D., FRSC, MBA, is President and CEO of CiVentiChem, a premier contract R&D services company located in Research Triangle Park of North Carolina. At CiVentiChem, Bhaskar takes overall strategic and management responsibility of the company.
Lepakshi
"Lepakshi Bio Pharma cluster" offers world class environment and infrastructure for global players in the areas of bio pharma, livestock biotechnology, health care diagnostics, medical technology, food technology. The cluster is positioned to utilize the synergies of larger biotech eco system in Bangalore.
Distingueshed Lectures
Dr. Lukas Utiger
Throughout the 20th century, healthcare has focused on the palliative treatment of underlying health symptoms. In fact, much of the modern pharmaceutical industry was built on small molecule approaches to mitigate symptoms - it is largely an industry addressing sickness, not wellness.
Roger Williams
The concept of a biological medicine has been with humanity for many hundreds of years. Indeed, the first pharmacopoeia of the United States, now in its 34th revision, provided recipes for crude mixtures drawn from nature. It was only later that the promise of medicines as chemicals, drawn from the precepts of Paracelsus, came to dominate the therapeutic armamentarium for medicines of the 20th century.
Genome Valley Award
BIG, China
Beijing Institute of Genomics (BIG) of Chinese Academy of Sciences (CAS) was officially founded on November 28, 2003 as one of the youngest institutes of life sciences. BIG currently has a total number of 184 faculty and staff members, including 1 Academia Sinica academician, 1 CAS academician, 17 research fellows including 7 "100 Talents Program" scientists. At present BIG has 197 graduate students.
Dr. Anji Reddy
Dr. K Anji Reddy is a B.Sc.-Tech in Pharmaceuticals and Fine Chemicals from Bombay University and PhD in Chemical Engineering from National Chemical Laboratory, Pune. He is the Founder & Chairman of Dr. Reddy's Laboratories Limited (DRL).
Health
CV Rao
Despite several advances in the radiological assessments and extensive chemotherapeutic testing for number of decades, the overall five-year survival of all patients diagnosed with pancreatic cancer is still only 2% to 3%. The lack of progress against this malignancy is thought to be due to no early diagnosis and striking therapeutic resistance.
Dhanunjaya Lakkreddy
Associate Professor of Medicine, Division of Cardiovascular Medicine, University of Kansas Hospitals, Kansas City, KS, USA.
DR. K.V Balasubramaniam
The Global Immunization and Vision Strategy (GIVS), adopted by WHO and UNICEF in 2005, has set ambitious targets for eradication and control of vaccine preventable diseases.
Dr. Prasada Reddy
Global business environment is characterized by three prominent features: 1) Liberalization of economies worldwide, particularly for trade and investment (both at macro and sector-levels); 2) Changes in science, technology and innovation (STI) dynamics.
Dr. Prem Kumar Reddy
The Polo like kinases play key roles in mitosis. While the upregulation of PLK1 in cancer is well documented and PLK3 has been demonstrated to be a tumor suppressor, little is known about the oncogenic significance of PLK2. PLK2 kinase activity is essential for centriolar duplication and is also believed to play a regulatory role in the survival pathway by physically stabilizing the TSC1/2 complex in tumor cells in hypoxic conditions.
Dr. Radha Rangarajan
The global pharmaceutical industry has experienced significant challenges in terms of profitability in the last decade. The collective R&D spend by the large pharmaceutical companies has been estimated at $50 billion annually, but the number of truly innovative medicines resulting from these investments has remained small.
Dr. Rakesh Verma
Prescient Life Sciences is a global Life Sciences consultancy with offices in London, New Jersey, San Francisco, Delhi and Beijing. We offer a refreshing change from regular consultancy in that all of our recommendations are supported by necessary evidence.
Dr. Vijay Chandru
Vijay Chandru is an alumnus of BITS Pilani where he trained in Electrical Engineering and went on to get a doctorate from MIT, Cambridge, USA. Chandru is an academic and an entrepreneur who was named in the 50 Pioneers of Change by India Today in 2008.
Dr. Arvind Mahajan
As for today 50% of known human pathogens are zoonotic and 75% of newly emerging infectious organisms come from animals. With the ever increasing global demand for food, intensive animal rearing for food production,
Dr. Jogi
Bio-similars or follow-on biologics are emerging as effective alternatives to the potentially toxic and cyto-toxic small molecules in the treatment of many organic diseases and cancers. Ever increasing market share of the bio-similars holds a great promise for the Indian entrepreneurs.
Dr.Vinod Kubrekar
I will assess this likely evolution and fragmentation of the biosimilar market in my presentation. I believe that this richness of options would lead it to be a much larger market than the biosimilars itself. There will be regulatory challenges and they would be overcome on case-by-case basis depending on the quality of the science behind a particular approach.
Harinder Singh
I have recently transitioned from a life in academia to one in the biotech world. Deep down the reason that I was attracted to join Genentech is because it attempts to combine the best elements of an academic culture with those from the translational research and commercial domains.
Mr. HariBuggana
Hari Buggana is the Managing Director of InvAscent - the Investment Advisor of Evolvence India Life Sciences Fund. Prior to this, Hari was a consultant with McKinsey & Company.
Prof. Hescheler
Prof. Hescheler is Chairman and Director of the Institute of Neurophysiology at the University of Cologne. He has been working with embryonic stem cells of the mouse for over 20 years.
Rayprasad
Several promising new vaccines have just been licensed or are at advanced stages of development in US/Europe as well as in India and the developing world in general.
Santosh Varalwar
The driving force behind the phenomenal growth of Vivimed Labs Ltd, Mr. Santosh Varalwar has had a highly successful entrepreneurial journey starting with an active role in WS Pharmaceuticals in 1985.
MediAsia
Arunachalam Dharmarajan
Professor Arun Dharmarajan is a Winthrop Professor and Associate Dean (South Asia Research Initiatives) and has the responsibility of teaching and research in the School of Anatomy and Human Biology. As Associate Dean for South Asia Research Initiative, Professor Dharmarajan's primary role is to establish strong research links with Universities and Research Institutes in India.
D. Laune
Our SysDiag lab is a CNRS/Bio-Rad Research center for Identification of new biomarkers and development of specific diagnostic tools for early and differential diagnosis of complex diseases (Alzheimer, diabetes, cardiovascular diseases, infectious diseases…) in cerebrospinal fluid, urine and blood.
Dr. Bernward Garthoff
Dr. Bernward Garthoff is the Biotechnology Representative for the Federal State of North Rhine-Westphalia, Germany, of the Biotech Cluster BIO.NRW.
Dr. Cozzone
Proton localized magnetic resonance spectroscopy (MRS) is a method of noninvasive exploration of human neurochemistry based on the magnetic resonance phenomenon. This exploration of brain metabolism, performed without any injection, detects neuronal, glial, and membrane markers.
Dr. G Luzergues
Speaker in the engineering school of Luminy ( ESIL) in Marseille on the aspects of the functioning of the French system of health and the European Directives (CE mark).
Dr. H Meyer
The diagnosis of Parkinson disease (PD), a degenerative disorder of the central nervous system, relies on the recognition of clinical symptoms appearing in a late stage of pathogenesis. At this stage of PD only the treatment of the clinical symptoms is feasible, a therapy that is capable to stop the progression of the disease is still not available.
Dr. Jagat Reddy Junutula
Jagath Reddy Junutula, PhD joined Genentech, Inc. in 2001 and is currently a Senior Scientist in the Research and Early Development Division (gRED). He obtained his PhD in 1997 from the Indian Institute of Science, Bangalore, India, and did post-doctoral research in Germany as an Alexander von Humboldt fellow and at Stanford University.
Dr. Luc Chausson
To be released on the European market, medical devices have to be CE marked. European institutions like European parliament, Council of European Union and European Commission establish and approve the Medical Device Directives (Medical Device 93/42/EEC, Active Implantable Medical Devices 90/385/EEC, In Vitro Diagnostic devices 98/79/EC,…).
Dr. Prabhakar Ranjekar
Role of micronutrients and traditional medicine in cancer and during pregnancy, foetal life, early childhood for prevention of non-communicable disorders in later life.
Dr. Rupam Borghain
Prediction of vulnerability, evolution, prognosis of Alzheimer's Disease (AD) and search for novel therapeutic agents are the major objects of current neurosciences research. Hence, it is vital to identify patients with AD, early in the disease course.
GSK Velu
A first generation entrepreneur of over 22 years of experience in healthcare segment, who changed the way the medical technology and diagnostics industry works today, bringing them within the reach of medical practitioners across India.
Kaiser Jamil
Dr. Kaiser Jamil has contributed significantly in the area of cancer biology and Bioinformatics and impact on QOL/ affecting human health using and developing various Biomarker assays. Her recent research combines unusual versatility in adopting different areas like Molecular Biology, Bioinformatics and Drug-Gene Interactions for demonstrating the effect of some xenobiotics and metal ion pollutants that cause various malignancies in at least 2% of the population.
Oliver Blin
Olivier BLIN was born in Marseille (France). Resident from Paris Hospitals, certified in neurology and psychiatry (1988), he also qualified the Ph.D. « Doctorat d'Etat de Biologie Humaine (1990), and a MBA from Ecole Centrale Paris (1997). He became full Professor in Clinical Pharmacology. A MBA Olivier BLIN is responsible of the Clinical Pharmacology Unit-CIC of the Public Hospital in Marseille (AP-HM) and of a CNRS-University research team.
Rajendra Prasad
Rajendra Prasad earned the BSc and MSc degrees from Lucknow University, Lucknow (1963-67), after which he joined Central Drug Research Institute Lucknow where he worked on lipids of biological membranes under the supervision of Dr. C.R. Krishna Murthy (1970).
Sundararajan
Cancer stem cells are a very small subset of cancer cells and possess characteristics very similar to normal stem cells, in particular, the capacity for self-renewal, multipotency and relative quiescence. These chemo- and radiation resistant cells are responsible for maintaining tumor volume leading to therapy failure and recurrence. This necessitates alternate treatments to existing cancers and many novel treatment modalities are being investigated to specifically target this small group of cells.
Vinayak Ravi
The need for better emergency diagnostics and epidemiological preparedness, along with rising healthcare costs, has increased the demand for affordable point-of-need (PON) test platforms with high sensitivity, specificity, and rapid turnaround time. Responding to such demands, we have developed handheld, portable point of need systems for immuno-diagnstics as well as for molecular diagnostics on an OEM basis.
